US 12,427,201 B2Granted

Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

AssigneeSutro Biopharma, Inc.

InventorsRyan Stafford, Alice Yam, Xiaofan Li, Gang Yin, Toni Kline, Cristina Abrahams, Venita De Almeida

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

Claims27

Dependent claims

An antibody conjugate comprising an antibody of the IgG class wherein the antibody specifically binds to folate receptor alpha (FOLR1) linked site-specifically to at least one payload moiety, wherein the antibody comprises, and wherein the antibody comprises:

(i) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
19;
a CDR-H2 comprising SEQ ID NO:
137;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:78;
a CDR-H2 comprising SEQ ID NO:
196;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
4;
a CDR-H2 comprising SEQ ID NO:
122;
and a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:63;
a CDR-H2 comprising SEQ ID NO:
181;
a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(v) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
8;
a CDR-H2 comprising SEQ ID NO:
126;
and a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:67;
a CDR-H2 comprising SEQ ID NO:
185;
a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
12;
a CDR-H2 comprising SEQ ID NO:
130;
and a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(viii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:71;
a CDR-H2 comprising SEQ ID NO:
189;
a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ix) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
14;
a CDR-H2 comprising SEQ ID NO:
132;
and a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(x) a VH comprising:
a CDR-H1 comprising SEQ ID NO:73;
a CDR-H2 comprising SEQ ID NO:
191;
a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
56;
a CDR-H2 comprising SEQ ID NO:
174;
and a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:115;
a CDR-H2 comprising SEQ ID NO:
233;
a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xiii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
58;
a CDR-H2 comprising SEQ ID NO:
176;
and a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
or
(xiv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:117;
a CDR-H2 comprising SEQ ID NO:
235;
a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305.

187 more elements

An antibody conjugate comprising an antibody of the IgG class, said antibody comprising:

(i) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
19;
a CDR-H2 comprising SEQ ID NO:
137;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:78;
a CDR-H2 comprising SEQ ID NO:
196;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
4;
a CDR-H2 comprising SEQ ID NO:
122;
and a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:63;
a CDR-H2 comprising SEQ ID NO:
181;
a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(v) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
8;
a CDR-H2 comprising SEQ ID NO:
126;
and a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:67;
a CDR-H2 comprising SEQ ID NO:
185;
a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
12;
a CDR-H2 comprising SEQ ID NO:
130;
and a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(viii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:71;
a CDR-H2 comprising SEQ ID NO:
189;
a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ix) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
14;
a CDR-H2 comprising SEQ ID NO:
132;
and a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(x) a VH comprising:
a CDR-H1 comprising SEQ ID NO:73;
a CDR-H2 comprising SEQ ID NO:
191;
a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
56;
a CDR-H2 comprising SEQ ID NO:
174;
and a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:115;
a CDR-H2 comprising SEQ ID NO:
233;
a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xiii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
58;
a CDR-H2 comprising SEQ ID NO:
176;
and a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
or
(xiv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:117;
a CDR-H2 comprising SEQ ID NO:
235;
a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305,
linked site-specifically to at least one payload moiety, and wherein the antibody conjugate has the structure of Conjugate P:
wherein n is an integer from 1 to 6.

189 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/572,557Filed 16 Sep 2019 · continuation
Priority: 18 Sep 2017
Published: US 2020/0147229 A114 May 2020
Granted: 30 Sep 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 47/6803
Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent: drugs conjugated to an antibody or…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Family

Application62/560,064Us provisional application · filed 18 Sep 2017
Application16/133,383Parent of this continuation · filed 17 Sep 2018
US 2020/0147229 A1Pre-grant publication · published 14 May 2020
US 10,596,270 B2Parent of this continuation
US 2019/0083641 A1Published application
US 12,427,201 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

(i) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
19;
a CDR-H2 comprising SEQ ID NO:
137;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:78;
a CDR-H2 comprising SEQ ID NO:
196;
a CDR-H3 comprising SEQ ID NO:
255;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
4;
a CDR-H2 comprising SEQ ID NO:
122;
and a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(iv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:63;
a CDR-H2 comprising SEQ ID NO:
181;
a CDR-H3 comprising SEQ ID NO:
240;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(v) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
8;
a CDR-H2 comprising SEQ ID NO:
126;
and a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:67;
a CDR-H2 comprising SEQ ID NO:
185;
a CDR-H3 comprising SEQ ID NO:
244;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(vii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
12;
a CDR-H2 comprising SEQ ID NO:
130;
and a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(viii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:71;
a CDR-H2 comprising SEQ ID NO:
189;
a CDR-H3 comprising SEQ ID NO:
248;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(ix) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
14;
a CDR-H2 comprising SEQ ID NO:
132;
and a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(x) a VH comprising:
a CDR-H1 comprising SEQ ID NO:73;
a CDR-H2 comprising SEQ ID NO:
191;
a CDR-H3 comprising SEQ ID NO:
250;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xi) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
56;
a CDR-H2 comprising SEQ ID NO:
174;
and a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:115;
a CDR-H2 comprising SEQ ID NO:
233;
a CDR-H3 comprising SEQ ID NO:
292;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
(xiii) a VH comprising:
a CDR-H1 comprising SEQ ID NO:
58;
a CDR-H2 comprising SEQ ID NO:
176;
and a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305;
or
(xiv) a VH comprising:
a CDR-H1 comprising SEQ ID NO:117;
a CDR-H2 comprising SEQ ID NO:
235;
a CDR-H3 comprising SEQ ID NO:
294;
and a VL comprising:
a CDR-L1 comprising SEQ ID NO:
299;
a CDR-L2 comprising SEQ ID NO:
302;
and a CDR-L3 comprising SEQ ID NO:
305.

187 more elements

Facts

Application

16/572,557Filed 16 Sep 2019 · continuation

Priority

18 Sep 2017

Published

US 2020/0147229 A114 May 2020

Granted

30 Sep 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 47/6803
Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent: drugs conjugated to an antibody or…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Family

Application62/560,064Us provisional application · filed 18 Sep 2017

Application16/133,383Parent of this continuation · filed 17 Sep 2018

US 2020/0147229 A1Pre-grant publication · published 14 May 2020

US 10,596,270 B2Parent of this continuation

US 2019/0083641 A1Published application

US 12,427,201 B2This patent

From the US filing history. Foreign family members aren’t listed.